We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
JEMPERLI (GlaxoSmithKline Australia Pty Ltd)
Product name
JEMPERLI
Date registered
Evaluation commenced
Decision date
Approval time
214 (255 working days)
Active ingredients
dostarlimab
Registration type
EOI
Indication
JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer.